XML 78 R36.htm IDEA: XBRL DOCUMENT v3.20.1
Quarterly Financial Data (Unaudited) (Tables)
 12 Months Ended
Dec. 31, 2019
Quarterly Financial Information Disclosure [Abstract]  
Quarterly Financial Information
Selected quarterly financial data for the years ended December 31, 2019 and 2018 are as follows:
 
 
2019
 
 
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
Revenue
 
$
25

 
$
434

 
$
527

 
$
310

Net loss (1) (2)
 
(5,286
)
 
(5,220
)
 
(5,816
)
 
(9,981
)
Basic and diluted loss per common share
 
$
(0.12
)
 
$
(0.12
)
 
$
(0.09
)
 
$
(0.13
)
 
 
2018
 
 
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
Revenue
 
$
36

 
$
19

 
$
57

 
$
6

Net loss (1)
 
(5,509
)
 
(6,825
)
 
(5,324
)
 
(4,755
)
Basic and diluted loss per common share
 
$
(0.14
)
 
$
(0.17
)
 
$
(0.13
)
 
$
(0.11
)
___________
(1) - Net loss includes a non-cash unrealized gain (loss) related to the fair value adjustment of the common stock warrant liability of $370, $(113), $103, $24 in the three months ended March 31, 2019, June 30, 2019, September 30, 2019, and December 31, 2019 and ($128), ($915), $581, and $186 in the three months ended March 31, 2018, June 30, 2018, September 30, 2018, and December 31, 2018, respectively.
(2) - Net loss in the three months ended December 31, 2019 includes $3,750 of research and development expense related to license fees owed to Northwestern University in connection with the receipt of the Allergan Upfront Payment during that period. Refer to Note 3, Collaborative Research and License Agreements for more information on the Allergan Upfront Payment and Note 14, Commitments and Contingencies for more information on the Northwestern University License Agreements.